US.BIIB · Biogen

{
  "risk": {
    "level": "Elevated",
    "reason": "risk management score >= 5/10",
    "position": {
      "score": 1.1,
      "details": {
        "atrPct": 3.9203743969688634,
        "turnoverUsdM": 189.88356732856,
        "liquidityPoints": 0.4,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.BIIB",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 185.9958,
      "strength_details": {
        "ma_score": 2,
        "atr_score": 1,
        "rsi_score": 2,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 7.8,
      "take_profit_price": 217.1035,
      "target_multiplier": 1.9,
      "technical_strength": 1.53,
      "take_profit_percent": 7.6
    },
    "positionPoints": 1.1,
    "stopLossPoints": 1.2,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 7.840748793937727,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 57.7,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 49.7,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 8
  },
  "market": {
    "ma20": 202.4295,
    "ma50": 200.8006,
    "close": 201.82,
    "prevClose": 202.95,
    "avgVolume20": 1456188,
    "volumeRatio": 0.65,
    "changePercent": -0.56
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 8,
    "details": {
      "ret_5d": 0.008394174078145245,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 8,
      "vcp_bonus": 0,
      "vol_ratio": 0.6400097954852336,
      "ret_points": 4,
      "vol_points": 0,
      "range_ratio": 0.4922136871386172,
      "volat_points": 0,
      "day_range_pct": 0.019869189383153785,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 4,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 57.7,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.2,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 44,
        "contribution": 2.2
      },
      {
        "raw": 10,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 50,
        "contribution": 10
      },
      {
        "raw": 6.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 44,
        "contribution": 6.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 5.7,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 57,
        "contribution": 5.7
      },
      {
        "raw": 19.2,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 64,
        "contribution": 19.2
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 49.7,
    "details": [
      "基本面分析總分: 2.2/5分",
      "資金流分析總分: 10/20分",
      "市場環境分析總分: 6.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 5.7/10分",
      "技術信號分析總分: 19.2/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.2,
      "資金流": 10,
      "市場環境": 6.6,
      "情緒分析": 4,
      "技術信號": 19.2,
      "風險管理": 5.7
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.5,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.5,
          "marginPoints": 0,
          "turnoverUsdM": 189.88356732856,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 2.4,
          "obvPoints": 4,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.BIIB",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 3,
            "details": {
              "qqq": {
                "ma20": 699.88099675,
                "ma50": 714.8264005399999,
                "name": "QQQ",
                "close": 700.070007,
                "points": 1
              },
              "spy": {
                "ma20": 746.0140036500002,
                "ma50": 745.31840316,
                "name": "SPY",
                "close": 757.66998,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.9203743969688634,
          "atrPoints": 2,
          "cciPoints": 1.6,
          "vixPoints": 0,
          "marketTrendPoints": 3
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141087814,
                "url": "https://finnhub.io/api/news?id=79c85db271e7d964af8764123ce35f25b0d723af71c3b68905827751789ec757",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biotech company Biogen (NASDAQ:BIIB) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 3.4% year on year to $2.74 billion. Its non-GAAP profit of $3.60 per share was 75.8% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785599277,
                "headline": "BIIB Q2 Deep Dive: Portfolio Expansion and Pipeline Readouts Drive Upbeat Outlook"
              },
              {
                "id": 141063522,
                "url": "https://finnhub.io/api/news?id=34ff54a8cc17094f79ad56c7f69dd8888cad6a9c08f1569e4bc5d2b14f34c7e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen Inc. has released its second-quarter 2026 results, reporting revenue of US$2.74 billion versus US$2.65 billion a year earlier, while net income dropped to US$97.5 million and diluted EPS from continuing operations fell to US$0.66 from US$4.33. Despite modest revenue growth for both the quarter and first half of 2026, Biogen’s profitability compressed sharply, with six‑month net income falling to US$417.0 million from US$875.3 million, highlighting a widening gap between sales...",
                "category": "company",
                "datetime": 1785391731,
                "headline": "Biogen (BIIB) Is Up 5.8% After Earnings Compression Amid Revenue Growth – Is Profitability Peaking?"
              },
              {
                "id": 141058596,
                "url": "https://finnhub.io/api/news?id=bcb4bce5f67ee0ae88d03f86cff4bcf7e28aac5f04e8b3f4a884222a40c71393",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen Inc (BIIB) reports a 3% revenue increase, driven by a robust growth portfolio and strategic acquisitions, despite facing market challenges.",
                "category": "company",
                "datetime": 1785359014,
                "headline": "Biogen Inc (BIIB) Q2 2026 Earnings Call Highlights: Strong Growth in Core Pharmaceuticals and ..."
              },
              {
                "id": 141056937,
                "url": "https://finnhub.io/api/news?id=0873deb1760e30eec26325069b9aef7c10238b0e43c98c712ebff7fe9c252aae",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "Biogen Inc. (BIIB) Q2 2026 Earnings Call July 29, 2026 8:30 AM EDTCompany ParticipantsTim Power - Head of Investor RelationsChristopher Viehbacher -...",
                "category": "company",
                "datetime": 1785340401,
                "headline": "Biogen Inc. (BIIB) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141054426,
                "url": "https://finnhub.io/api/news?id=8eb2366f1687d4f584f048ddee4270fe9f7e41d7c7636c04d18e7c104927e5e0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
                "category": "company",
                "datetime": 1785333603,
                "headline": "Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates"
              },
              {
                "id": 141053250,
                "url": "https://finnhub.io/api/news?id=9e848640eda925c11e40e855bcdf8fb354486ca8917fc7e3a92131a508529c90",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q2 CY2026, with sales up 3.4% year on year to $2.74 billion. Its non-GAAP profit of $3.60 per share was 75.8% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785327345,
                "headline": "Biogen (NASDAQ:BIIB) Reports Upbeat Q2 CY2026"
              },
              {
                "id": 141053252,
                "url": "https://finnhub.io/api/news?id=b478927a46056feeba626bbe3305da8048a1d5551702c18e7ec0f8a91ffcb9e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) delivered earnings and revenue surprises of +18.42% and +9.40%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785324603,
                "headline": "Biogen Inc. (BIIB) Q2 Earnings and Revenues Top Estimates"
              },
              {
                "id": 141042768,
                "url": "https://finnhub.io/api/news?id=0340072648f7776869bda85db5951d8e27a9090fec1d821da354dca9741fc893",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Wednesday before market hours. Here’s what to look for.",
                "category": "company",
                "datetime": 1785246062,
                "headline": "Biogen (BIIB) Reports Q2: Everything You Need To Know Ahead Of Earnings"
              }
            ],
            "raw_source": [
              {
                "id": 141102903,
                "url": "https://finnhub.io/api/news?id=1616416f52964b33626780df4bbf688e25cb5403a3309b1f71b9e4583bd1f513",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Amgen, Pfizer, Eli Lilly, Merck and Novo Nordisk are set to report Q2 results this week after a strong start for pharma earnings. Which names could beat forecasts?",
                "category": "company",
                "datetime": 1785778200,
                "headline": "Are These 5 Pharma Stocks Set to Surpass Q2 Earnings Forecasts?"
              },
              {
                "id": 141100761,
                "url": "https://finnhub.io/api/news?id=7b92ac9f780895129eea930a6651202fe06c8fc6ae0dee90844ddfa38d9415cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.",
                "category": "company",
                "datetime": 1785767640,
                "headline": "4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates"
              },
              {
                "id": 141087814,
                "url": "https://finnhub.io/api/news?id=79c85db271e7d964af8764123ce35f25b0d723af71c3b68905827751789ec757",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biotech company Biogen (NASDAQ:BIIB) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 3.4% year on year to $2.74 billion. Its non-GAAP profit of $3.60 per share was 75.8% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785599277,
                "headline": "BIIB Q2 Deep Dive: Portfolio Expansion and Pipeline Readouts Drive Upbeat Outlook"
              },
              {
                "id": 141081582,
                "url": "https://finnhub.io/api/news?id=fbee925dabbe6f460ef2b4b28c54e17bf35b8224f7677ab26790e7608838499f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "The biotech's shares have stumbled after a guidance change, and investors are weighing whether this is the moment to step in or step aside.",
                "category": "company",
                "datetime": 1785526149,
                "headline": "Is The Recent Pullback In Alnylam Stock An Opportunity Or A Trap?"
              },
              {
                "id": 141070848,
                "url": "https://finnhub.io/api/news?id=891e489f7895a66c6bdabdf73f2f1af2c3b647435235df64066b2c206308d815",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Ionis beats Q2 revenues and earnings estimates as commercial growth offsets tough comparisons, while reaffirming its 2026 outlook.",
                "category": "company",
                "datetime": 1785433560,
                "headline": "IONS Beats Q2 Earnings & Sales Estimates, Reiterates '26 Outlook"
              },
              {
                "id": 141079500,
                "url": "https://finnhub.io/api/news?id=f7cc43de75b589ff54cd3ec172ffea5c55862ac82812b9c6bf226cf2329f5cdd",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "UBS  analyst Michael Yee   maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $225 to $240.",
                "category": "company",
                "datetime": 1785429109,
                "headline": "UBS Maintains Buy on Biogen, Raises Price Target to $240"
              },
              {
                "id": 141070208,
                "url": "https://finnhub.io/api/news?id=d73b935868f1be90c5afd21a24440f30d18e87b322411a6f119d7215a4343536",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "HC Wainwright & Co.  analyst Andrew S. Fein   maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $237 to $251.",
                "category": "company",
                "datetime": 1785424208,
                "headline": "HC Wainwright & Co. Maintains Buy on Biogen, Raises Price Target to $251"
              },
              {
                "id": 141070209,
                "url": "https://finnhub.io/api/news?id=901908e305222fa30e9e6df0498c809f80e261bb0ad34d56f46e01fbbefb8753",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Morgan Stanley  analyst Matthew Harrison   maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from $222 to $231.",
                "category": "company",
                "datetime": 1785417953,
                "headline": "Morgan Stanley Maintains Equal-Weight on Biogen, Raises Price Target to $231"
              },
              {
                "id": 141070210,
                "url": "https://finnhub.io/api/news?id=b44380759e05ae65208e0b6dbbba1adc3d7d3f1d8cf6459d7262c85dbd266ddb",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "RBC Capital  analyst Brian Abrahams   maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $242 to $240.",
                "category": "company",
                "datetime": 1785417745,
                "headline": "RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $240"
              },
              {
                "id": 141070211,
                "url": "https://finnhub.io/api/news?id=0f088f6cf39f50aea7042a163a8e5f109458aad370cfec3ed0a722618b889a23",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Canaccord Genuity  analyst Sumant Kulkarni   maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $245 to $248.",
                "category": "company",
                "datetime": 1785411715,
                "headline": "Canaccord Genuity Maintains Buy on Biogen, Raises Price Target to $248"
              },
              {
                "id": 141070212,
                "url": "https://finnhub.io/api/news?id=a414e6454339cbb94ed5dfe671357e898c62fa92dfcf33a3370ad3652392f1d0",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "TD Cowen  analyst Phil Nadeau   maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $215 to $225.",
                "category": "company",
                "datetime": 1785411686,
                "headline": "TD Cowen Maintains Buy on Biogen, Raises Price Target to $225"
              },
              {
                "id": 141070213,
                "url": "https://finnhub.io/api/news?id=a64cdda1ea51d6f09da7ae5e53045a8db9be569b5e7f6ef480a3d9a27d372fe3",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Wedbush  analyst Laura Chico   maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $201 to $215.",
                "category": "company",
                "datetime": 1785404453,
                "headline": "Wedbush Maintains Neutral on Biogen, Raises Price Target to $215"
              },
              {
                "id": 141063522,
                "url": "https://finnhub.io/api/news?id=34ff54a8cc17094f79ad56c7f69dd8888cad6a9c08f1569e4bc5d2b14f34c7e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen Inc. has released its second-quarter 2026 results, reporting revenue of US$2.74 billion versus US$2.65 billion a year earlier, while net income dropped to US$97.5 million and diluted EPS from continuing operations fell to US$0.66 from US$4.33. Despite modest revenue growth for both the quarter and first half of 2026, Biogen’s profitability compressed sharply, with six‑month net income falling to US$417.0 million from US$875.3 million, highlighting a widening gap between sales...",
                "category": "company",
                "datetime": 1785391731,
                "headline": "Biogen (BIIB) Is Up 5.8% After Earnings Compression Amid Revenue Growth – Is Profitability Peaking?"
              },
              {
                "id": 141059663,
                "url": "https://finnhub.io/api/news?id=e878947f767b5f20331c91f468e260ff4861a905da81a14521dec058a3a731ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "The company published its second-quarter results on Wednesday morning.",
                "category": "company",
                "datetime": 1785368580,
                "headline": "Why Biogen Stock Topped the Market Today"
              },
              {
                "id": 141058596,
                "url": "https://finnhub.io/api/news?id=bcb4bce5f67ee0ae88d03f86cff4bcf7e28aac5f04e8b3f4a884222a40c71393",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen Inc (BIIB) reports a 3% revenue increase, driven by a robust growth portfolio and strategic acquisitions, despite facing market challenges.",
                "category": "company",
                "datetime": 1785359014,
                "headline": "Biogen Inc (BIIB) Q2 2026 Earnings Call Highlights: Strong Growth in Core Pharmaceuticals and ..."
              },
              {
                "id": 141056947,
                "url": "https://finnhub.io/api/news?id=b603a696c3ad32b26eea35e7acb3b9e37eb7f5a6acf4903dee490a13eb42463a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Moby summary of Biogen Inc.'s Q2 2026 earnings call",
                "category": "company",
                "datetime": 1785353490,
                "headline": "Biogen Inc. Q2 2026 Earnings Call Summary"
              },
              {
                "id": 141055975,
                "url": "https://finnhub.io/api/news?id=f88459dae0f7166f972d7a518413d9253735fcca2063a2c6ca5bdc1fee27b7d4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Teva Pharmaceutical Industries climbed above an important chart level Wednesday, after the company's bullish guidance overshadowed mixed second-quarter results.  Teva earnings thinned to 2 cents a share after subtracting costs from an acquisition.  The profit came in below the consensus estimate of 5 cents a share.",
                "category": "company",
                "datetime": 1785345656,
                "headline": "Drugmakers Climb On Q2 Reports, Even As One Misses Profit Views"
              },
              {
                "id": 141055796,
                "url": "https://finnhub.io/api/news?id=642b6eda2a5c39263b9ab36de6e6bb1ae6e1ad94fee7e1fb4751cd9d7b9dc625",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen’s growth portfolio, which includes one closely watched Alzheimer’s drug, is a bright spot in the second quarter.",
                "category": "company",
                "datetime": 1785342060,
                "headline": "Why Biogen Stock Is Resisting a Market Downturn After Earnings"
              },
              {
                "id": 141056937,
                "url": "https://finnhub.io/api/news?id=0873deb1760e30eec26325069b9aef7c10238b0e43c98c712ebff7fe9c252aae",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "Biogen Inc. (BIIB) Q2 2026 Earnings Call July 29, 2026 8:30 AM EDTCompany ParticipantsTim Power - Head of Investor RelationsChristopher Viehbacher -...",
                "category": "company",
                "datetime": 1785340401,
                "headline": "Biogen Inc. (BIIB) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141055977,
                "url": "https://finnhub.io/api/news?id=fed3577fc8a0490e8bfa454f6857e864769160cb170f1e970b3df7f0416ac869",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen tops Q2 earnings and revenue estimates as growth drugs fuel sales, offset MS declines, and support a higher 2026 revenue and EPS outlook.",
                "category": "company",
                "datetime": 1785337740,
                "headline": "Biogen's Q2 Earnings Beat, New Drugs Drive Sales, 2026 Guidance Raised"
              },
              {
                "id": 141054425,
                "url": "https://finnhub.io/api/news?id=1a0ccbe58908a26310dec99566bfa6d8d2006cab56d23e1638b6e1b1e9ec0d57",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (NASDAQ:BIIB) reported second-quarter 2026 total revenue of $2.7 billion, up 3% from a year earlier, as growth products and the recently completed acquisition of Apellis contributed to results. Core pharmaceutical revenue rose 4% year over year to $1.8 billion, while the company’s growth port",
                "category": "company",
                "datetime": 1785333859,
                "headline": "Biogen Q2 Earnings Call Highlights"
              },
              {
                "id": 141054426,
                "url": "https://finnhub.io/api/news?id=8eb2366f1687d4f584f048ddee4270fe9f7e41d7c7636c04d18e7c104927e5e0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
                "category": "company",
                "datetime": 1785333603,
                "headline": "Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates"
              },
              {
                "id": 141059866,
                "url": "https://finnhub.io/api/news?id=3a1b396f3a193bab276960903df1609cee8d23faa0ff5a2169aa11d3ea6a588a",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/29/Biogen-World-Headquarters-At-225-Binney-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Biogen beat second-quarter earnings and revenue estimates, raised its 2026 guidance, and reported pipeline progress.",
                "category": "company",
                "datetime": 1785332206,
                "headline": "Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio"
              },
              {
                "id": 141053249,
                "url": "https://finnhub.io/api/news?id=5d800f468473e98a2c5100133b735d2060b32339332301e0be3b6672512a30d4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (NASDAQ:BIIB) reported stronger-than-expected second-quarter results on Wednesday, with revenue and adjusted earnings exceeding Wall Street forecasts as its expanding portfolio of growth products continued to offset weakness in its legacy multiple sclerosis business. The biotechnology company posted revenue of $2.",
                "category": "company",
                "datetime": 1785327401,
                "headline": "Biogen Beats Second-Quarter Expectations as Growth Portfolio Drives Revenue Higher"
              },
              {
                "id": 141053250,
                "url": "https://finnhub.io/api/news?id=9e848640eda925c11e40e855bcdf8fb354486ca8917fc7e3a92131a508529c90",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q2 CY2026, with sales up 3.4% year on year to $2.74 billion. Its non-GAAP profit of $3.60 per share was 75.8% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785327345,
                "headline": "Biogen (NASDAQ:BIIB) Reports Upbeat Q2 CY2026"
              },
              {
                "id": 141053066,
                "url": "https://finnhub.io/api/news?id=5abf50436158576a31979517d05fbd83f05d7ec4faf8fd94ceed8b0a4eaa6c1b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen’s growth portfolio, which includes one closely watched Alzheimer’s drug, is a bright spot in the second quarter.",
                "category": "company",
                "datetime": 1785326520,
                "headline": "Why This Drugmaker’s Earnings Guidance Cut Doesn’t Tell the Full Story"
              },
              {
                "id": 141053252,
                "url": "https://finnhub.io/api/news?id=b478927a46056feeba626bbe3305da8048a1d5551702c18e7ec0f8a91ffcb9e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) delivered earnings and revenue surprises of +18.42% and +9.40%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785324603,
                "headline": "Biogen Inc. (BIIB) Q2 Earnings and Revenues Top Estimates"
              },
              {
                "id": 141053885,
                "url": "https://finnhub.io/api/news?id=1f15877a1001ae15dd5a3cd545b026512debdef79ac455207e35e507121673e3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2238013673/image_2238013673.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "Biogen Inc. upgraded to Buy: Q2 revenue +3%, LEQEMBI traction, and felzartamab catalysts drive upside. Click for this BIIB earnings update.",
                "category": "company",
                "datetime": 1785324567,
                "headline": "Biogen: The Turnaround Is Real Enough To Buy (Rating Upgrade)"
              },
              {
                "id": 141054427,
                "url": "https://finnhub.io/api/news?id=846973aa10402577b458d69661dc5bd7cac39f8cf95aa30249bc7a697e6bbc93",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Better-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall Street that they can hit ambitious revenue targets.",
                "category": "company",
                "datetime": 1785323580,
                "headline": "Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push"
              },
              {
                "id": 141052252,
                "url": "https://finnhub.io/api/news?id=6db8a7113e7159ccb704f68f588809abf63564a3140aaf4b72b0f3becbd1eda4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Investing.com -- Biogen reported second-quarter revenue and adjusted profit above analysts’ estimates on Wednesday, helped by 24% growth in its Growth Portfolio and stronger revenue from recently acquired products, although sales of its Alzheimer’s drug Leqembi narrowly missed expectations.",
                "category": "company",
                "datetime": 1785321928,
                "headline": "Biogen Q2 revenue, adjusted EPS beat estimates as growth portfolio lifts sales"
              },
              {
                "id": 141052253,
                "url": "https://finnhub.io/api/news?id=9afab3629373368e5c62797f2b5ea2a6a51d921425c4d56407f4fbea96cd923f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's second quarter report. In total, sales of JPY 29.3 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 179 million, which is an increase of approximately 10 percent compared to the royalty recorded by BioArctic for the second quarter 2025.",
                "category": "company",
                "datetime": 1785321000,
                "headline": "Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026"
              },
              {
                "id": 141052175,
                "url": "https://finnhub.io/api/news?id=b87a3f7d28d6995fee006d6de2c58bc3e201493a75af9c698a57fcac9470ce53",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen’s growth portfolio, which includes one closely watched Alzheimer’s drug, is a bright spot in the second quarter.",
                "category": "company",
                "datetime": 1785320940,
                "headline": "Biogen Raises Revenue Guidance as Growth Portfolio Outpaces Legacy Blockbuster Drugs"
              },
              {
                "id": 141059867,
                "url": "https://finnhub.io/api/news?id=9e65778ac7e74a8a1b29d5c5cdbfa634c6d8c3b7f8af1c640fafc222fa95a58a",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Biogen (NASDAQ:BIIB) raises FY2026 Adj EPS guidance from $15.25-$16.25 to $15.85-$16.85 vs $12.83 analyst estimate..",
                "category": "company",
                "datetime": 1785316342,
                "headline": "CORRECTION: Biogen Raises FY2026 Adj EPS Guidance from $15.25-$16.25 to $15.85-$16.85 vs $12.83 Est"
              },
              {
                "id": 141052662,
                "url": "https://finnhub.io/api/news?id=7cf6e4c88002252010d020c92bf427ffb5da1c6c29f3d2f7bdad8f3f2406a64e",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "2026-07-29. The following slide deck was published by Biogen Inc.",
                "category": "company",
                "datetime": 1785315705,
                "headline": "Biogen Inc. 2026 Q2 - Results - Earnings Call Presentation"
              },
              {
                "id": 141059868,
                "url": "https://finnhub.io/api/news?id=139dcfaedd31fc5664a1a362635ac5497d3c437a712004310622e5a88b464dda",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Barclays  analyst Emily Field   maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from $185 to $200.",
                "category": "company",
                "datetime": 1785311880,
                "headline": "Barclays Maintains Equal-Weight on Biogen, Raises Price Target to $200"
              },
              {
                "id": 141042768,
                "url": "https://finnhub.io/api/news?id=0340072648f7776869bda85db5951d8e27a9090fec1d821da354dca9741fc893",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Wednesday before market hours. Here’s what to look for.",
                "category": "company",
                "datetime": 1785246062,
                "headline": "Biogen (BIIB) Reports Q2: Everything You Need To Know Ahead Of Earnings"
              },
              {
                "id": 141041720,
                "url": "https://finnhub.io/api/news?id=4340760a7e45a140e669280168a7ec7a122e4f7bb43f8b9c7ee0b3f947ca31d1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "HRMY, ACAD, BIIB, INSM and AGIO are set to report Q2 results, with positive Earnings ESPs suggesting potential earnings surprises.",
                "category": "company",
                "datetime": 1785229080,
                "headline": "The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals"
              },
              {
                "id": 141035128,
                "url": "https://finnhub.io/api/news?id=b58d464b27d7f23f9a829bbedeecdcfeaa6027ba0087c79c62c1a13671ff8765",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 results, setting up closely watched earnings reports.",
                "category": "company",
                "datetime": 1785170160,
                "headline": "Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?"
              },
              {
                "id": 141036510,
                "url": "https://finnhub.io/api/news?id=2f62a044959d35ec044e5dd29682f89b92d8b07064ef346a4b280cee421af697",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2150679757/image_2150679757.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "Design Therapeutics' DT-216P2 showed 6.4-point mFARS gains in Friedreich’s ataxia, but data is early. Click here to read the latest analysis on DSGN stock.",
                "category": "company",
                "datetime": 1785169866,
                "headline": "A Deeper Dive Into Design Therapeutics"
              },
              {
                "id": 141007897,
                "url": "https://finnhub.io/api/news?id=0bbfb641eb9799606d45569051d0eff09b47cebdacb86a61c292ffbb1e342cfe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "BIIB heads into Q2 results with new launches expected to offset weaker MS drug sales as investors watch Leqembi trends and the Apellis deal impact.",
                "category": "company",
                "datetime": 1784905020,
                "headline": "Biogen Q2 Earnings: Can New Drugs Counter Falling MS Sales?"
              },
              {
                "id": 140994984,
                "url": "https://finnhub.io/api/news?id=8f14a0b5b1108d73e7c2e51a39cd5ce106eb77cf45b56fc1f41202eec13050d1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1784815229,
                "headline": "Will PTC Therapeutics (PTCT) Report Negative Earnings Next Week? What You Should Know"
              },
              {
                "id": 140983335,
                "url": "https://finnhub.io/api/news?id=01fd7e79a66bf3e187e0e19193f967093ecf3293cf0691383240a4c4a9bf7bec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1784728822,
                "headline": "Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for"
              },
              {
                "id": 140978801,
                "url": "https://finnhub.io/api/news?id=31950cdc680aaed03c87b13cd3cc791d4998f3781cee034e435a3218c2641737",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/511995022/image_511995022.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "Biogen’s (BIIB) FDA-approved injectable Leqembi cuts infusion costs but risks brain bleeds; see how diranersen compares and why neither may boost valuation.",
                "category": "company",
                "datetime": 1784677610,
                "headline": "Biogen And The Limitation Of The Tau Approach To Alzheimer's Disease"
              },
              {
                "id": 140970681,
                "url": "https://finnhub.io/api/news?id=5fd866ee8c6005a3bf2bce88f2207d39cf7b4ae098a282a1c16b59bc648a03f4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.",
                "category": "company",
                "datetime": 1784637986,
                "headline": "3 Profitable Stocks We Steer Clear Of"
              },
              {
                "id": 140977482,
                "url": "https://finnhub.io/api/news?id=64f9c13c86306fd6c2b32735dbdfed93f5355ffbcb04efe640e8ece4dc41e5f4",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Guggenheim  analyst Brad Canino   maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $260 to $280.",
                "category": "company",
                "datetime": 1784627315,
                "headline": "Guggenheim Maintains Buy on Biogen, Raises Price Target to $280"
              },
              {
                "id": 140977483,
                "url": "https://finnhub.io/api/news?id=50ab814353c7a88ebe2a3e822ce2e437a28bce905e2132afad430896dc91d5db",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "B of A Securities  analyst Jason Zemansky   maintains Biogen (NASDAQ:BIIB) with a Neutral and lowers the price target from $217 to $215.",
                "category": "company",
                "datetime": 1784622854,
                "headline": "B of A Securities Maintains Neutral on Biogen, Lowers Price Target to $215"
              },
              {
                "id": 140962286,
                "url": "https://finnhub.io/api/news?id=c3c0b46f3f2825ecb2bcaeb068893828261cdbba575a6b03bffbef65f86c6c60",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "By Daniella Parra VERAXA Biotech said it received positive scientific advice from Germany’s Paul-Ehrlich-Institute supporting a preclinical development plan for its experimental BiTAC-TCE cancer therapy platform. The feedback provides greater regulatory clarity and reduces some early-stage development risk as the company advances its lead candidate toward clinical trials, it said. READ MORE The Cancer […] The post VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform appeared first",
                "category": "company",
                "datetime": 1784564140,
                "headline": "VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform"
              },
              {
                "id": 140949639,
                "url": "https://finnhub.io/api/news?id=e66915f61a8325ddeb71fb49741e5b27430464cdf2d2993d7cfdc35c9c26a86d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1366552805/image_1366552805.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "Stoke Therapeutics outlook: Phase 3 Dravet program catalysts, strong cash runway, and upside from partnerships. Click for more on STOK stock.",
                "category": "company",
                "datetime": 1784427316,
                "headline": "Stoke Therapeutics: Its Dravet Syndrome Lead Asset Enters The Last Stretch"
              },
              {
                "id": 140922873,
                "url": "https://finnhub.io/api/news?id=afe3ab276daa701b92f1c15194aafe1b2b9513fc46ee50671f3a9b8925c2a053",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "By Daniella Parra Slate Medicines, a private biotech company developing new treatments for migraine and other headache disorders, has appointed Mark W. Hahn to its Board of Directors, they said. The company said Hahn brings more than 25 years of life sciences leadership experience, including serving as CFO of Verona Pharma, where he helped guide […] The post Slate Medicines Appoints Mark W. Hahn to Board of Directors appeared first on ExecEdge.",
                "category": "company",
                "datetime": 1784218733,
                "headline": "Slate Medicines Appoints Mark W. Hahn to Board of Directors"
              },
              {
                "id": 140919017,
                "url": "https://finnhub.io/api/news?id=0574ac5a1c3475f752dcc68f3aeb53389a6a1e7115c90f8fba19919eab9e016a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Synapticure, a leading virtual care company dedicated to improving access and outcomes for patients and caregivers living with neurodegenerative diseases, today announced the launch of a virtual ataxia care program. This program can help to provide timely access to specialized care for adults living with ataxias — a group of neurological conditions characterized by progressive loss of coordination, balance, and motor function. Synapticure partnered with Biogen Inc. (Nasdaq: BIIB) to support dise",
                "category": "company",
                "datetime": 1784202420,
                "headline": "Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide"
              },
              {
                "id": 140909943,
                "url": "https://finnhub.io/api/news?id=b23004b2e6eee8b89d9c2ca4bbc24aea8227d09c1937a787636ff354968adf86",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen’s 14.4% return over the past six months has outpaced the S&P 500 by 6.2%, and its stock price has climbed to $192.84 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.",
                "category": "company",
                "datetime": 1784128637,
                "headline": "3 Reasons to Avoid BIIB and 1 Stock to Buy Instead"
              },
              {
                "id": 140909556,
                "url": "https://finnhub.io/api/news?id=078bec1491fb0d2386bee78b68cb24d0e112102bf4d9c5e65ba67d4356afdbbf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "BIIB's Alzheimer's drug data presentation reaffirms a phase II setback as investors weigh plans to advance diranersen in phase III despite missed goals.",
                "category": "company",
                "datetime": 1784127060,
                "headline": "Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data"
              },
              {
                "id": 140908577,
                "url": "https://finnhub.io/api/news?id=ef10b299ed3f00e94085a86fcc122614315b2cac68067065e1ece1e64bce7109",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Michael J. Parini as Chief Legal Officer, effective August 3, 2026. Parini will serve as a member of Biogen's Executive Committee and report to Christopher A. Viehbacher, President and Chief Executive Officer. In this role, Mr. Parini will have responsibility for oversight of Biogen’s global legal and compliance functions. “Michael brings to Biogen a rare combination of deep legal an",
                "category": "company",
                "datetime": 1784117700,
                "headline": "Biogen Appoints Michael J. Parini as Chief Legal Officer"
              },
              {
                "id": 140907578,
                "url": "https://finnhub.io/api/news?id=c9a17f44db5a334c035e6ea894b335b18b541a949a6999656ebfaf5a0e0d5595",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Data released by Biogen at AAIC26 appears to have spooked investors, with an 8.17% drop in share price.",
                "category": "company",
                "datetime": 1784114717,
                "headline": "AAIC26: Biogen stock drops after unveiling tau-targeting ASO data"
              },
              {
                "id": 140907005,
                "url": "https://finnhub.io/api/news?id=4c34e63184f76bf7a57fc384113207254a1cea90cf20bffe8628c9e23db58712",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1046071676/image_1046071676.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "As evidence piled up that amyloid is not going to be the answer in Alzheimer's, tau has been on the upswing. Now we have another test: Diranersen, an antisense oligo from Biogen and Ionis.",
                "category": "company",
                "datetime": 1784096400,
                "headline": "Tau In The Clinic, Again"
              },
              {
                "id": 140905338,
                "url": "https://finnhub.io/api/news?id=8e3e5f4d6f541304dd96b8ca7c08abee57966960c4ef5141f7dcf81cdf146ba9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) is back in focus after fresh Alzheimer’s data, including new real world results for LEQEMBI and Phase 2 findings for tau targeting candidate diranersen, gave investors more information on the company’s neurology pipeline. See our latest analysis for Biogen. Despite the positive Alzheimer’s headlines, Biogen’s 1 day share price return was down 8.17% and the 7 day share price return was down 6.68%. However, the year to date share price return of 7.95% and 1 year total shareholder...",
                "category": "company",
                "datetime": 1784081483,
                "headline": "Biogen (BIIB) Following Fresh Alzheimer’s Data Is The Upside Story Still Intact"
              },
              {
                "id": 140901109,
                "url": "https://finnhub.io/api/news?id=deff9c90bb7e909239d4818d05eb00911aa88c16bd160a2315a273ea8e21cb70",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "BIIB",
                "summary": "Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Tuesday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1784055900,
                "headline": "Discover which S&P500 stocks are making waves on Tuesday."
              },
              {
                "id": 140897980,
                "url": "https://finnhub.io/api/news?id=f61a94464a694de7ff39e9d9539738b692e155b597a056dcbf1cdda87ce22960",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "FEATURE  Stocks were rising Tuesday as investors responded to cooler- than-expected U.S. inflation data for June, a slew of bank earnings reports, and a profit warning from IBM that sent the stock down sharply.",
                "category": "company",
                "datetime": 1784055840,
                "headline": "IBM, Goldman Sachs, SK Hynix, Micron, AMD, Apple, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 140901726,
                "url": "https://finnhub.io/api/news?id=843f0eefaa2e7301af9fcdf72ad9e106a5d1948594c88e2c6d424cf6fb246178",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (NASDAQ:BIIB) said data from its Phase 2 CELIA study of diranersen in early Alzheimer’s disease provide proof of concept for the tau-targeting therapy, despite the trial not meeting its primary endpoint of demonstrating a predefined dose-response pattern. The company presented the update dur",
                "category": "company",
                "datetime": 1784055729,
                "headline": "Biogen Backs Alzheimer’s Tau Drug for Phase 3 Despite Trial Miss"
              },
              {
                "id": 140903730,
                "url": "https://finnhub.io/api/news?id=f64b8b857c66457bc04df5fec443525de7d9d706504395c3e55696b5300cd6df",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "2026-07-14. The following slide deck was published by Biogen Inc.",
                "category": "company",
                "datetime": 1784055667,
                "headline": "Biogen Inc. (BIIB) Presents at Alzheimer's Association International Conference (AAIC Meeting) 2026 - Slideshow"
              },
              {
                "id": 140901727,
                "url": "https://finnhub.io/api/news?id=83d154d750f01f5513fbb6bfce3a640282e0c0a9d877d79ca5f38b08d275222c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen’s mid-stage trial of diranersen did not meet its main goal of showing a clear relationship between higher doses and better results.",
                "category": "company",
                "datetime": 1784054309,
                "headline": "BIIB Stock On Track For Worst Day In 2 Years After RBC Questions If Alzheimer’s Drug Benefits Will Replicate In Further Study"
              },
              {
                "id": 140901438,
                "url": "https://finnhub.io/api/news?id=9fd95fbb80f47cce96cfbcae493bee66c1a8f0e6fab86029428940d7057e1de6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "The presentation on  Biogen’s  experimental Alzheimer’s treatment at a medical meeting Tuesday was supposed to boost confidence in its drug’s prospects.  Instead, Biogen stock is down 6%, to $197.  Tuesday’s presentation on the drug diranersen, at London’s Alzheimer’s Association International Conference, left attendees confused about what to conclude from Biogen’s Phase 2 study known as CELIA.",
                "category": "company",
                "datetime": 1784052540,
                "headline": "Biogen’s Alzheimer’s Drug Leaves Questions Unanswered, and That’s a Problem"
              },
              {
                "id": 140900024,
                "url": "https://finnhub.io/api/news?id=dc7da346181b0f2ceb39f461126fe7731235d0cb02fbf8edee8bfb962e0c285e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "The mid-stage study missed its primary goal, and the drug's lowest dose outperformed higher doses in ways the company cannot yet explain",
                "category": "company",
                "datetime": 1784050581,
                "headline": "Biogen stock falls 8% on Alzheimer's drug diranersen trial data"
              },
              {
                "id": 140902562,
                "url": "https://finnhub.io/api/news?id=a820614b62bcd511dc1e0ec626c3a18e6709881c065fed16f0a31886d326a49b",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "Biogen Inc. (BIIB) Alzheimer's Association International Conference (AAIC Meeting) 2026 July 12, 2026 11:15 AM EDTCompany ParticipantsTim Power - Head of...",
                "category": "company",
                "datetime": 1784050148,
                "headline": "Biogen Inc. (BIIB) Presents at Alzheimer's Association International Conference (AAIC Meeting) 2026 Transcript"
              },
              {
                "id": 140899157,
                "url": "https://finnhub.io/api/news?id=f91db0d4afe78455d4f9df00a17b8cf4e2e599781c52c715e4b5f564b7ba2873",
                "image": "https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp",
                "source": "ChartMill",
                "related": "BIIB",
                "summary": "Curious about which S&P500 stocks are generating unusual volume on Tuesday? Find out below.",
                "category": "company",
                "datetime": 1784048700,
                "headline": "These S&P500 stocks have an unusual volume in today's session"
              },
              {
                "id": 140898964,
                "url": "https://finnhub.io/api/news?id=76a3fb9d03f8bf894bf401ec3d9d7e7a7980e4769b9be8dd004e0986d25fa30d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "BIIB",
                "summary": "Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday.",
                "category": "company",
                "datetime": 1784046901,
                "headline": "These S&P500 stocks are moving in today's session"
              },
              {
                "id": 140899731,
                "url": "https://finnhub.io/api/news?id=ab9efa283f15df1648247f3f9e34e0ef7c686344770d8bd769c997f910e901a6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "BIIB secures FDA approval for Leqembi Iqlik, letting early Alzheimer's patients start with a weekly at-home autoinjector instead of biweekly IV infusions.",
                "category": "company",
                "datetime": 1784045640,
                "headline": "Biogen Wins FDA Approval for Subcutaneous Starter Dose of Leqembi"
              },
              {
                "id": 140898429,
                "url": "https://finnhub.io/api/news?id=153a92e7c1d3306b0bf3dac06054d4aef60c4ba31ec9ccace2d09042ec9629b7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Investing.com -- Biogen Inc. (NASDAQ:BIIB) shares fell nearly 9% following the Phase 2 CELIA readout of its highly anticipated Alzheimer’s therapy, diranersen. While the drug achieved a major scientific milestone by robustly clearing tau pathology, an unexpected inverse dose response—where the lowest dose performed the best—left Wall Street analysts confused and triggered a sell-off. Diranersen missed its primary endpoint: proving a dose-dependent response on the CDR-SB, a key measure of cogniti",
                "category": "company",
                "datetime": 1784044872,
                "headline": "Biogen tumbles 8.7% as breakthrough Alzheimer’s data is clouded by dosing paradox"
              },
              {
                "id": 140898430,
                "url": "https://finnhub.io/api/news?id=a9e06211335096289748ba9a37a41671ec2c348e9241124092af0e8e0ffebc5e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen and Ionis said Tuesday their tau-targeting Alzheimer's treatment slowed cognitive decline by 26% over the course of 18 months.",
                "category": "company",
                "datetime": 1784042341,
                "headline": "Biogen Slumps As Alzheimer's Study Leaves 'More Questions Than Answers'"
              },
              {
                "id": 140898431,
                "url": "https://finnhub.io/api/news?id=aa2dcbdc57f26604d5c33242d8e2a691b612fb54dcc749217defc31eaa1192bb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Real-World Findings Support Long-Term Benefits of Continuous Treatment with LEQEMBI and Provide Important Insights into Treatment Experience Outside of a Clinical Trial SettingTOKYO and CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Study show that nearly 83% of early Alzheimer’s disease (AD) patients enrolled in the study remained stable (75.9%) or",
                "category": "company",
                "datetime": 1784042280,
                "headline": "LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment"
              },
              {
                "id": 140897584,
                "url": "https://finnhub.io/api/news?id=e89def7c0ac59e2c2278d3bdc4ee12a87bb928101e8b6a227c378a65a8572717",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "BIIB",
                "summary": "Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Tuesday. Stay informed about the latest market trends.",
                "category": "company",
                "datetime": 1784039701,
                "headline": "What's going on in today's session: S&P500 gap up and gap down stocks"
              },
              {
                "id": 140898432,
                "url": "https://finnhub.io/api/news?id=2850f575f0c0ac756ca144ad8124dc0026e814bffab100311cd4dabf6dd56b3e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Eisai and Biogen recently received FDA approval for LEQEMBI IQLIK, a once-weekly subcutaneous autoinjector initiation dose that allows adults with early Alzheimer’s disease to start and continue treatment at home instead of relying solely on intravenous infusions in clinics. This at-home option, supported by data showing exposure equivalent to IV dosing and high ease-of-use ratings from patients and care partners, could meaningfully change how Alzheimer’s therapies are delivered and accessed...",
                "category": "company",
                "datetime": 1784038479,
                "headline": "How Investors Are Reacting To Biogen (BIIB) At-Home LEQEMBI Autoinjector Approval"
              },
              {
                "id": 140898433,
                "url": "https://finnhub.io/api/news?id=335e15dbc6b4c650190727b5035fcb51690cdbf9586238b463e0e01264c1a27d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "IONS doses first patient in the phase I/II ASCEND study of ION337, marking a key step in developing a potential disease-modifying treatment for Dravet syndrome.",
                "category": "company",
                "datetime": 1784037840,
                "headline": "Ionis Begins Dosing in Phase I/II Dravet Syndrome Study"
              },
              {
                "id": 140897184,
                "url": "https://finnhub.io/api/news?id=12dae6227d028324d7acc54f0812561d6047c17fa2eee53843c805ce883612df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen and Ionis said Tuesday their tau-targeting Alzheimer's treatment slowed cognitive decline by 26% over the course of 18 months.",
                "category": "company",
                "datetime": 1784037012,
                "headline": "Can Biogen Score Another Win In Alzheimer's Disease?"
              },
              {
                "id": 140897185,
                "url": "https://finnhub.io/api/news?id=5125b91b018246b3e62db8e2c2ea2b077856ecc0b47816e0538f5927102d1e96",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen Inc. (NASDAQ:BIIB) traded higher after releasing encouraging Phase 2 data for its experimental Alzheimer’s treatment, diranersen, with results showing meaningful reductions in tau pathology alongside improvements across several measures of cognitive decline.",
                "category": "company",
                "datetime": 1784036917,
                "headline": "Biogen Shares Rise After Positive Phase 2 Alzheimer’s Trial Results (BIIB)"
              },
              {
                "id": 140897186,
                "url": "https://finnhub.io/api/news?id=c60c35a9692c2c3683e6fb2211ac66f07db16a4a666a1524b83019e046512e28",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Clinical outcomes: Diranersen demonstrated efficacy across all studied doses at 18 months, with consistent results across multiple prespecified clinical endpoints; the 60 mg dose showed the strongest response with slowing of clinical decline on the cognitive endpoints—42% on ADAS-Cog13 and 50% on MMSE—alongside a 26% slowing on CDR-SBBiomarker response: Diranersen is the first tau-directed therapy to demonstrate robust reductions in both CSF total tau, with mean reductions of 50–65%, and brain t",
                "category": "company",
                "datetime": 1784034900,
                "headline": "Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease"
              },
              {
                "id": 140900720,
                "url": "https://finnhub.io/api/news?id=982d691f7bdf984c9054330e7605835e8313c537db0cb3b10f02c37d43a0b613",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/14/Biogen-World-Headquarters-At-225-Binney-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Biogen stock drops 9% as Phase 2 diranersen data raises analyst questions, despite Phase 3 plans and a new weekly LEQEMBI FDA approval.",
                "category": "company",
                "datetime": 1784029742,
                "headline": "Why Is Biogen Stock Falling Tuesday?"
              },
              {
                "id": 140900721,
                "url": "https://finnhub.io/api/news?id=93fd7a9af496e79891ad78bb9310c38b4aa0dc82811f9bf6f330a567d276d683",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB) announced today that results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Study show that nearly 83% of early Alzheimer’s disease (AD) patients",
                "category": "company",
                "datetime": 1784028514,
                "headline": "Eisai And Biogen Present Real‑World LEADER Study Data At AAIC Showing Nearly 83% Of Early Alzheimer’s Patients Remained Stable Or Improved On LEQEMBI Therapy Over ~17 Months, With Consistent Results Across Diverse Groups."
              },
              {
                "id": 140896087,
                "url": "https://finnhub.io/api/news?id=befb0ac9f26bb3b83c29adbffc620cf85b5952f9878e208e6f66245506b91a64",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.",
                "category": "company",
                "datetime": 1784026991,
                "headline": "1 Mid-Cap Stock to Target This Week and 2 We Find Risky"
              },
              {
                "id": 140897843,
                "url": "https://finnhub.io/api/news?id=520d796eabd894cbc585550389a8e02addcd2d87cb2f7df5a7f677886dfd3db0",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Biogen Inc. (Nasdaq: BIIB) today announced data from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with early Alzheimer’s",
                "category": "company",
                "datetime": 1784020668,
                "headline": "Biogen's Diranersen Demonstrates Efficacy Throughout All Doses In Phase 2 CELIA Trial Of Alzheimer’s Disease; Consistent Efficacy Seen Across Multiple Prespecified Secondary Endpoints Including Clinical Dementia Rating Sum Of Boxes"
              },
              {
                "id": 140891446,
                "url": "https://finnhub.io/api/news?id=f9c0d5351e0b9b5a757351be14bd40c1d9a9fd87679c441cf74bd62fa0039c50",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.) U.S. launch of LEQEMBI IQLIK as an initiation dose planned for late August 2026 TOKYO and CAMBRIDGE, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a once-weekly lecanemab-irmb subc",
                "category": "company",
                "datetime": 1783978680,
                "headline": "FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease"
              },
              {
                "id": 140890177,
                "url": "https://finnhub.io/api/news?id=8e5d11b1bb207cfa389f939c829219b507d74d7f791eeac7746b1e3d00e9430e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "The decision marks a major shift in how patients can begin therapy for early Alzheimer’s disease.",
                "category": "company",
                "datetime": 1783970517,
                "headline": "BIIB Stock Jumps 5% — Analysts Raise Price Targets After FDA Clears Alzheimer’s Treatment For At-Home Use"
              },
              {
                "id": 140900723,
                "url": "https://finnhub.io/api/news?id=ca9d4d6a80beba733a20279a421f2f5e1a11de4e8ca3e19c8c9b9fc25d4cbfc2",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "TOKYO and CAMBRIDGE, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB), announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License",
                "category": "company",
                "datetime": 1783964529,
                "headline": "Eisai Co And Biogen Receive FDA's Approval For A Supplemental Biologics License Application For A Once-Weekly Lecanemab-Irmb Subcutaneous Injection As An Initiation Dose For The Treatment Of Early Alzheimer’s Disease; U.S. Launch Of LEQEMBI IQLIK As An Initiation Dose Planned For Late August 2026"
              },
              {
                "id": 140888368,
                "url": "https://finnhub.io/api/news?id=8460d2a47f8d87174a291290655a443a37f1c416d86d29c3f103d568cf8f36e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "A global chip sector's retreat dragged the Nasdaq lower this morning, as oil surged today, July 13, 2026.",
                "category": "company",
                "datetime": 1783961298,
                "headline": "Stock Market Today, July 13: SK Hynix Tumbles 15% in South Korea, Leading Semiconductor Drop at Midday"
              },
              {
                "id": 140888306,
                "url": "https://finnhub.io/api/news?id=57bedb73d41617dfb4ded24cd68d45f832ba1061ba4289dba14cb6cdb4b41c61",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Energy names help cushion the Dow as oil jumps on U.S.–Iran tensions and investors brace for key earnings and inflation data, today, July 13, 2026.",
                "category": "company",
                "datetime": 1783960490,
                "headline": "Stock Market Today, July 13: Energy Stocks Cushion Dow as Tech Slides on Geopolitical Tensions"
              },
              {
                "id": 140900724,
                "url": "https://finnhub.io/api/news?id=b9875427c33851f5f86319e415a4699bcd47afc86e558a1f0abdcc0860d23a4f",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-home-starting-dose-alzheimers-disease-treatment",
                "category": "company",
                "datetime": 1783952611,
                "headline": "FDA Grants Approval For At-Home Starting Dose For Alzheimer's Treatment Leqembi"
              },
              {
                "id": 140885931,
                "url": "https://finnhub.io/api/news?id=d9bd3e5a447e59b21f811bc30301952ad049da7bb5153d18da437fe995ccd6e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "American Express, Biogen upgraded: Wall Street's top analyst calls",
                "category": "company",
                "datetime": 1783950101,
                "headline": "American Express, Biogen upgraded: Wall Street's top analyst calls"
              },
              {
                "id": 140886004,
                "url": "https://finnhub.io/api/news?id=fa383cbd374bde41988e115d4cbc03b8495b70bbef286e24aa0b170187d47707",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Investing.com -- Truist Securities upgraded Biogen to Buy from Hold and raised its price target to $235 from $190, citing growing confidence in the company’s Alzheimer’s and immunology pipeline ahead of several major clinical data readouts over the next two years.",
                "category": "company",
                "datetime": 1783945865,
                "headline": "Truist upgrades Biogen to Buy on Alzheimer’s, pipeline optimism ahead of key data"
              },
              {
                "id": 140887976,
                "url": "https://finnhub.io/api/news?id=4c3d77f1a79e40782699f426e87e3204d2534ab1d16dfaf918d148c20850134c",
                "image": "https://image.cnbcfm.com/api/v1/image/108199413-17580401582025-04-02t111950z_1380151334_rc2ipdal2hwb_rtrmadp_0_china-autos-nio.jpeg?v=1758040200&w=1920&h=1080",
                "source": "CNBC",
                "related": "BIIB",
                "summary": "These are the stocks posting the largest moves midday.",
                "category": "company",
                "datetime": 1783945286,
                "headline": "Stocks making the biggest moves midday: Nio, Braiin, AppLovin, SpaceX, SK Hynix & more"
              },
              {
                "id": 140886039,
                "url": "https://finnhub.io/api/news?id=deaa3f473f31c034a7009e39b7925d988ebd1dc02951a5d390f868977365a056",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen stock receives a bullish upgrade based on expectations the market will cheer the company’s detailed data on its experimental Alzheimer’s drug.",
                "category": "company",
                "datetime": 1783944900,
                "headline": "Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer’s Drug Study Details"
              },
              {
                "id": 140884998,
                "url": "https://finnhub.io/api/news?id=f1dc7be06c985cbaad59d7b32ea80790ba8f2868c8933acd882df5884c2cce60",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Pre-Market Stock Futures: Futures are trading lower as we get ready for the start of second-quarter earnings this week, after a solid winning week on Wall Street. Renewed strikes against Iran and a chip sell-off are weighing on shares on Monday. All of the major indices closed higher on Friday, except the small-cap Russell 2000, ... Here Are Monday’s Best Wall Street Analyst Research Calls: Atmos Energy, Best Buy, Biogen, Capital One, Costco, Disney, Papa John’s International, Shopify, and More",
                "category": "company",
                "datetime": 1783943713,
                "headline": "Here Are Monday’s Best Wall Street Analyst Research Calls: Atmos Energy, Best Buy, Biogen, Capital One, Costco, Disney, Papa John’s International, Shopify, and More"
              },
              {
                "id": 140886476,
                "url": "https://finnhub.io/api/news?id=43dc3f2fbf49498f6c2f58a8aa218fa43ebfdadaa4aa691f465c7bacff007dfd",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/13/Biogen-World-Headquarters-At-225-Binney-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Top Wall Street analysts changed their outlook on top names. Upgrade on NIO, COF, KEYS, BIIB, and AXP, see other ratings and consider buying BIIB.",
                "category": "company",
                "datetime": 1783926444,
                "headline": "This Biogen Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday"
              },
              {
                "id": 140887904,
                "url": "https://finnhub.io/api/news?id=db3a5579652ad3e0b4c058ea23ea680be5a0acb9b2db978431301472f4f8a05e",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Truist Securities  analyst Srikripa Devarakonda   upgrades Biogen (NASDAQ:BIIB) from Hold to Buy and raises the price target from $190 to $235.",
                "category": "company",
                "datetime": 1783923365,
                "headline": "Truist Securities Upgrades Biogen to Buy, Raises Price Target to $235"
              },
              {
                "id": 140883870,
                "url": "https://finnhub.io/api/news?id=7d9c0210dd5016813383530a69f6e183d6b937f6e47ce51e35e4ac29e44a8524",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen will present detailed Phase 2 study data for its experimental Alzheimer’s drug diranersen at a conference in London.",
                "category": "company",
                "datetime": 1783922400,
                "headline": "Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer’s?"
              },
              {
                "id": 140877927,
                "url": "https://finnhub.io/api/news?id=17b571e95a42f5259063ff686b5579fcb312c6b1706c1cbc9b26df7dd9423210",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partnersTOKYO and CAMBRIDGE, Mass., July 12, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that new data presented at the Alzheimer’s Association International Conference® (AAIC®) 2026 in London support that the LEQEMBI® (lecanemab) subcutaneous autoinjector (SC-AI) formulation offers e",
                "category": "company",
                "datetime": 1783869480,
                "headline": "LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026"
              },
              {
                "id": 140865207,
                "url": "https://finnhub.io/api/news?id=9604213b42f7aaf1d99a512e44898a5460795c6fe001db0655b9872a4f7dc48b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are rattling rivals across the RNA and rare-disease biotech space with more catalysts still ahead.",
                "category": "company",
                "datetime": 1783712254,
                "headline": "Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up"
              },
              {
                "id": 140860831,
                "url": "https://finnhub.io/api/news?id=70bace5e39146e0e64ac0773b15c6a491cc88cb329eb3be14cd2305070834fcd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "A look at the company's history of deep drawdowns shows the real risk shareholders are carrying today.",
                "category": "company",
                "datetime": 1783683335,
                "headline": "The Long Climb Back For Ionis Stock"
              },
              {
                "id": 140860719,
                "url": "https://finnhub.io/api/news?id=6ba326b18f13f774e3be2178a746990fab5ebabf0720aaaace213b57a39dd47e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 11.5% over the past six months, topping the S&P 500 by 4.3 percentage points.",
                "category": "company",
                "datetime": 1783683320,
                "headline": "1 Healthcare Stock with Solid Fundamentals and 2 We Brush Off"
              },
              {
                "id": 140852407,
                "url": "https://finnhub.io/api/news?id=93c73432a1e7673d15bfa810df331e53f5a7211080e7837c9bb9d89d1c99a5a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Systemic lupus erythematosus (SLE) is a chronic, complex autoimmune disease that can affect multiple organ systems, with disease severity and clinical manifestations varying considerably among patients. Despite significant advances in understanding its pathophysiology, SLE remains incurable, and current treatment strategies primarily focus on controlling disease activity, achieving remission or low disease activity, preventing irreversible organ damage, minimizing flares, and improving patients'",
                "category": "company",
                "datetime": 1783607460,
                "headline": "Systemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsight"
              },
              {
                "id": 140854879,
                "url": "https://finnhub.io/api/news?id=ce65ce2b089fd2cf93623cc7ccd97daa63d0593a026508e2b80549b26b9c0fb2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen is poised to announce its second-quarter results later this month, and analysts predict a double-digit drop in the company’s bottom-line figure.",
                "category": "company",
                "datetime": 1783600099,
                "headline": "Biogen's Q2 2026 Earnings: What to Expect"
              },
              {
                "id": 140850088,
                "url": "https://finnhub.io/api/news?id=e847fedf43124783edcb753cd3d81470a44d61c96f4b63d34a1e67601b823d3c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "On July 8, 2026, Moderna, Inc. appointed veteran financial executive Michael McDonnell, former Biogen CFO, to its Board of Directors and Audit Committee, while a federal advisory panel previously backed approval of the company’s first-of-its-kind mRNA influenza vaccine. Together with new programs in autoimmune disease, ovarian cancer and an AI-enabled research platform, these developments highlight Moderna’s push to broaden its mRNA franchise beyond COVID-19 and seasonal respiratory...",
                "category": "company",
                "datetime": 1783591935,
                "headline": "Will New Board Appointment And mRNA Flu Progress Change Moderna's (MRNA) Pipeline Diversification Narrative?"
              },
              {
                "id": 140841649,
                "url": "https://finnhub.io/api/news?id=46cf1067762772bdaff0bf3cd43eb85b6816d116b9c6119f06b2aaa77d698dba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather th",
                "category": "company",
                "datetime": 1783523510,
                "headline": "Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says"
              },
              {
                "id": 140853032,
                "url": "https://finnhub.io/api/news?id=4bb3e9d835d280ecf692c6bf349520f28767a8c3e8cc28198384b66c3201336e",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Morgan Stanley  analyst Matthew Harrison   maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and lowers the price target from $224 to $222.",
                "category": "company",
                "datetime": 1783513509,
                "headline": "Morgan Stanley Maintains Equal-Weight on Biogen, Lowers Price Target to $222"
              },
              {
                "id": 140842286,
                "url": "https://finnhub.io/api/news?id=7f70607135913a747248cddc872c58baa0448ad7a4f6f85e64e0d2058870d996",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/insider_trade_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "A July filing shows that Representative Maria Elvira Salazar reported a purchase in Brookfield Renewable (NYSE:BEP), valued between $50,008 and $225,000. The transaction date is listed as June 4, 2026, with the report",
                "category": "company",
                "datetime": 1783508412,
                "headline": "Congressional Trading Report: Rep. Maria Elvira Salazar Bought Over $50K In Brookfield Renewable Stock"
              },
              {
                "id": 140839747,
                "url": "https://finnhub.io/api/news?id=330deea0f937ba4fc68084a259ccf67f7595ac07a1ae24c96525a42b66911ac5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Former Biogen Chief Financial Officer brings more than 35 years of financial leadership and public company experience CAMBRIDGE, MA / ACCESS Newswire / July 8, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the appointment of Michael McDonnell ...",
                "category": "company",
                "datetime": 1783508400,
                "headline": "Moderna Appoints Michael McDonnell to Board of Directors"
              },
              {
                "id": 140833225,
                "url": "https://finnhub.io/api/news?id=2c21c0d4441f282ca0e4101ecb878317ea4a0bee0ef2c4db4c83a4b62cd67c1a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Ionis completes enrollment in the pivotal pediatric cohort of its phase III REVEAL study, advancing obudanersen toward potential regulatory submissions.",
                "category": "company",
                "datetime": 1783441680,
                "headline": "IONS Completes Enrollment in Pivotal Cohort of Angelman Syndrome Study"
              },
              {
                "id": 140833226,
                "url": "https://finnhub.io/api/news?id=87a299e9a577b4c947d1633e3db6e984a23d7b99ceb98ac5c64a949ffbb1ee28",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "category": "company",
                "datetime": 1783440605,
                "headline": "Why Biogen (BIIB) is Poised to Beat Earnings Estimates Again"
              },
              {
                "id": 140833326,
                "url": "https://finnhub.io/api/news?id=351483ad142a44454c749bbb1cc6bd5f4f8fc0f182938055e907b2088de11551",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "RBC Capital  analyst Brian Abrahams   maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $227 to $242.",
                "category": "company",
                "datetime": 1783424303,
                "headline": "RBC Capital Maintains Outperform on Biogen, Raises Price Target to $242"
              },
              {
                "id": 140830203,
                "url": "https://finnhub.io/api/news?id=75014b57a5eaea585df8853c5a378ed4fa238d1cdac808c53590a990dc26c001",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.",
                "category": "company",
                "datetime": 1783417140,
                "headline": "Vertex to acquire Crinetics in $10B foray into endocrine disease drugs"
              },
              {
                "id": 140823559,
                "url": "https://finnhub.io/api/news?id=5a144f07bedba347af467925be73da106be1e89722253a4d07e63d464f1aecad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Healthcare stocks are attractive in a choppy market. These funds, focusing on the broader sector, drugmakers, and biotechs, are worth a look.",
                "category": "company",
                "datetime": 1783361040,
                "headline": "3 Healthcare ETFs to Own in a Choppy Stock Market"
              },
              {
                "id": 140813366,
                "url": "https://finnhub.io/api/news?id=cb7628a5eb59c83089d360adea3cf8de59497534cd4b7268a622d945dc897161",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 29, it was reported that Biogen is scaling back Apellis Pharmaceuticals’ research pipeline and reducing its R&D staff, weeks after completing a $5.6 billion acquisition of the company. Biogen has suspended several legacy research programs, including Phase […]",
                "category": "company",
                "datetime": 1783256354,
                "headline": "Here is Why Biogen (BIIB) is One of the Most Undervalued NASDAQ Stocks to Buy Right Now"
              },
              {
                "id": 140805970,
                "url": "https://finnhub.io/api/news?id=75ba0c1561046e54f059b8e03c06190d1e9f2b1b0aa1de1a4668ec084aed3fa6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "This could be a key move for future growth.",
                "category": "company",
                "datetime": 1783153320,
                "headline": "Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors."
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 112,
            "discarded_article_count": 92
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 19.2,
        "grade": "一般",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 1.5,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1.5,
            "vcp_reason": "跌縮量(近10日4日)；站上MA50；升放量(近10日2日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 5,
              "vol_ref": 1452550,
              "down_days": 4,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 1103470,
              "avg_vol_20": 1470065,
              "avg_vol_30": 1452550,
              "range_pct_10": 0.10737290123016056,
              "range_pct_20": 0.16133187685403444,
              "range_pct_30": 0.1669309252338259,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.7596778079928401,
              "dist_to_20d_high": 0.07671892584290227,
              "down_shrink_days": 4,
              "breakout_level_20d": 218.59,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.6432175528875769
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 2.4,
          "shortRsiPoints": 0.4,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 1,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "較差",
        "items": {
          "position": {
            "score": 1.1,
            "details": {
              "atrPct": 3.9203743969688634,
              "turnoverUsdM": 189.88356732856,
              "liquidityPoints": 0.4,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.BIIB",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 185.9958,
            "strength_details": {
              "ma_score": 2,
              "atr_score": 1,
              "rsi_score": 2,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 7.8,
            "take_profit_price": 217.1035,
            "target_multiplier": 1.9,
            "technical_strength": 1.53,
            "take_profit_percent": 7.6
          },
          "positionPoints": 1.1,
          "stopLossPoints": 1.2,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 7.840748793937727,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.BIIB",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 7.9121,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.92
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "弱勢",
      "score": 4,
      "value": -15.74
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.0563
    },
    "kdj": {
      "d": 44.67,
      "j": 21.02,
      "k": 36.79,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 56.54
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 161344,
      "recentSlope": 136074.4,
      "previousSlope": -163540
    },
    "rsi": 58.57,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 198.7159,
      "position": "SAR喺價下",
      "distancePct": 1.54,
      "previousTrend": "上升"
    },
    "ma50": 200.8006,
    "macd": {
      "macd": 0.6764729193495214,
      "trend": "中性偏多",
      "signal": 0.7143437914372617,
      "histogram": -0.037870872087740315
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 202.0024,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.65,
      "score": 2,
      "avgVolume": 1456188,
      "currentVolume": 940856
    },
    "derived": {
      "ma20": 202.4295,
      "ma50": 200.8006,
      "prevClose": 202.95,
      "avgVolume10": 1101286,
      "avgVolume20": 1456188,
      "changePercent": -0.56,
      "avgVolumeForScore": 1456188
    },
    "ma_cross": {
      "ma20": 202.4295,
      "ma50": 200.8006,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "接近",
      "score": 6,
      "prevMa20": 202.7615,
      "prevMa50": 200.5202,
      "spreadPct": 0.81,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 193.5104,
      "upper": 211.3486,
      "position": "中間"
    },
    "rsi_short": 49,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.65
    }
  }
}

{
  "close": 201.82,
  "volume": 940856,
  "changePercent": -0.56
}